“We are very pleased to report progress in Cantargia’s second clinical program, CAN10. The data generated around safety and receptor binding is encouraging and confirms our predictions. We look forward to the continued evaluation in healthy subjects ahead of studies in patients,” said Göran Forsberg, CEO of
CAN10 is one of two clinical projects in the
The first four dose groups in healthy subjects have now concluded the treatment period. No safety concerns have been observed and the fifth dose group has started in accordance with the protocol. In addition, a receptor occupancy study shows that already at initial dose levels, the majority of IL1RAP molecules on immune cells are binding CAN10 in a dose dependent manner. This is in line with predictions from preclinical studies. Furthermore, biomarker samples taken during the study are currently analyzed to document blocking of IL-1 and IL-36 stimulation of immune cells. The first results from such studies are expected during Q2 2024. Studies in patients with psoriasis are expected to start H2 2024.
© Modular Finance, source